Business Context and Reporting Period
This Form 8-K is a current report filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on March 10, 2021, regarding events occurring on March 5, 2021. The filing details the results of the Company's annual meeting of stockholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following proposals were submitted to and voted upon by stockholders:
- Proposal 1 (Election of Directors): All eight nominees were elected. Votes ranged from approximately 22.8 million to 24.4 million "For" votes, with "Withheld" votes ranging from approximately 8.4 million to 10.0 million.
- Proposal 2 (Say-on-Pay): The advisory vote on executive compensation was approved with 32,752,645 votes "For" and 65,345 votes "Against."
- Proposal 3 (Frequency of Say-on-Pay): Stockholders approved a non-binding resolution to hold future advisory votes on executive compensation every three years (31,022,018 votes for 3 years).
- Proposal 4 (Auditor Ratification): The stockholders ratified Sadler, Gibb & Associates, LLC as the independent registered public accounting firm with 33,928,758 votes "For" and 949 votes "Against."
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the annual meeting.
Investor Verification Checklist
- Verify the correct registrant name is Enochian Biosciences Inc. (Ticker: ENOB), not Lunai Bioworks Inc.
- Confirm the election of the eight specific directors listed in Proposal 1.
- Note the shareholder decision to conduct executive compensation advisory votes every three years.
- Confirm the ratification of Sadler, Gibb & Associates, LLC as the independent auditor.